Cryoprecipitate reduced plasma is in the process of being merged into this article.
If possible, please edit only this article, as the article mentioned above may be turned into a redirect. Relevant discussion may be found on this article's talk page and/or the source article's talk page. (August 2018)
The resulting plasma has reduced levels of factor VIII (FVIII), von Willebrand factor (VWF), factor XIII (FXIII), fibronectin and fibrinogen. While the levels of FVIII are greatly reduced, levels of fibrinogen can be as much as 70% of original levels.
Cryosupernatant plasma can be used when replacement of FVIII is not required, and is indicated for plasma exchange for patients with thrombotic thrombocytopenic purpura (TTP) as well as for treatment of hemolytic-uremic syndrome (HUS) by plasma exchange, when plasma exchange is indicated.
- Shaz, Beth H.; Hillyer, Christopher D.; Roshal, Mikhail; Abrams, Charles S. (2013). Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. Newnes. p. 211. ISBN 9780123977885.
- Shehata, N., Blajchman, M. & Heddle, N. (21 Dec 2001). "Coagulation factors in fresh frozen plasma (FFP) and cryosupernatant (CSP) plasma (Abstract, in Abstracts of papers presented at the Joint Scientific Conference of the Canadian Society for Transfusion Medicine and Canadian Blood Services, 10–13 May 2001)". Transfusion Medicine. 11 (5): 391–401. doi:10.1046/j.1365-3148.2001.00115.x.
- Canadian Blood Services (2004). "F. Cryosupernatant, Leucocytes Reduced (LR)" (PDF). 2004 Circular of Information (PDF). p. 49. Retrieved December 2, 2009.